A simple blood test may spot hidden infections in kids with cancer

NCT ID NCT02417168

First seen Aug 19, 2026 · Last updated Aug 19, 2026

Summary

This pilot study asks whether a blood marker called procalcitonin can help predict bacteremia—a serious bacterial infection in the blood—in children with cancer who develop a fever. Currently, doctors rely on blood cultures, which can take up to 48 hours or give false negatives. The study will measure procalcitonin levels at admission, 12 hours, and 24 hours later in febrile pediatric oncology patients, with and without neutropenia, to see if elevated levels point to bacteremia. If successful, this could lead to fewer hospitalizations and less unnecessary antibiotic treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Procalcitonin level measurement
What this could lead to
If procalcitonin reliably predicts bacteremia, it could help doctors identify serious infections faster, potentially reducing unnecessary hospital stays and antibiotic use in children with cancer.
What could go wrong
This is a very small pilot study, so results may not be conclusive. Procalcitonin may not accurately distinguish bacterial from non-bacterial fevers in all cases, and the findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BACTEREMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CAMC Health Systems

    Charleston, West Virginia, 25304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.